A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT study

Controlled Clinical Trials

Volumn 18, Issue 1, 1997, Pages 93-119

  Syvänne, Mikko ^a,b   Taskinen, Marja Riitta ^a   Nieminen, Markku S ^a   Manninen, Vesa ^a   Kesäniemi, Y Antero ^a   Pasternack, Amos ^a   Nawrocki, James W ^a   Haber, Harry ^a   Frick, M Heikki ^a  

^a Lopid Coronary Angiography Trial I   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

coronary artery disease; fibric acid derivative; high density lipoproteins; progression regression studies; quantitative coronary angiography

Indexed keywords

GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; HUMAN; POPULATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCREENING;

EID: 0031080568     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(96)00091-8     Document Type: Article

References (118)

1. 1. Nikkilä E. Studies on the lipid-protein relationships in normal and pathologic sera and the effect of heparin on serum lipoproteins. Scand J Clin Lab Invest. 1953;5(Suppl 8):1-101.
2. 2. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
3. 3. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler A. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
4. 4. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
5. 5. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. Arch Intern Med. 1981;141:1128-1131.
6. 6. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol. 1990;46:649-654.
7. 7. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
8. 8. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA. 1990;264:3013-3017.
9. 9. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
10. 10. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
11. 11. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestryramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.
12. 12. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphil L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, and the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
13. 13. Waters D, Higginson L, Glastone P, Kimball B, Le May M, Boccuzzi SJ, Lespérance J. The CCAIT Study Group: effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
14. 14. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
15. 15. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KL, on behalf of the REGRESS Study Group: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
16. 16. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL: Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336:129-133.
17. 17. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, Hoberg E, Drinkmann A, Bacher F, Grunze M, Kübler W: Regular physical exercise and low-fat diet: effects on progression of coronary artery disease. Circulation. 1992;86:1-11.
18. 18. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, Sawin HS Jr, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
19. 19. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM, Farquhar JW. Effects of intensive multiple risk factor reductin on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
20. 20. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
21. 21. Miller M, Kwiterovitch PO Jr. Isolated low HDL-cholesterol as an important risk factor for coronary heart disease. Eur Heart J. 1990;11(Suppl H):9-14.
22. 22. Miller M, Mead LA, Kwiterowich PO Jr, Pearson TA. Dyslipidemias with desirable plasma total cholesterol levels and angigraphically demonstrated coronary artery disease. Am J Cardio. 1990;65:1-5.
23. 23. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-167.
24. 24. Fielding PE, Fielding CJ, Havel RJ, Kane JP, Tun P. Cholesterol net transport, esterification, and transfer in human hyperlipidemic plasma. J Clin Invest. 1983;71:449-460.
25. 25. Johnson WJ, Mahlberg FH, Rothblat GH, Phillipos MC. Cholesterol transport between cells and high-density lipoproteins. Biochem Biophys Acta. 1991;1085:273-298.
26. 26. Kunitake ST, La Sala KJ, Kane JP. Apolipoprotein A-I containing lipoproteins with pre-beta electrophoretic mobility. J Lipid Res. 1985;26:549-555.
27. 27. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
28. 28. Miller NE, La Ville A, Crook D. Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature. 1985;314:109-111.
29. 29. Bradimon JJ, Badimon L, Galvez A, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streak lesions in cholesterol-fed rabbits. Lab Invest. 1989;60:455-461.
30. 30. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234-1241.
31. 31. Badimon JJ, Fuster V, Badimon L. Role of high density lipoprotein in the regression of atherosclerosis. Circulation. 1992;86(Suppl III):III-86-III-94.
32. 32. Moncada S, Martin JF, Higgs A. Symposium on regressoin of atherosclerosis. Eur J Clin Invest. 1993;23:385-398.
33. 33. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
34. 34. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Lipid alterations and decline in the indidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
35. 35. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37-45.
36. 36. Blankenhorn DH, Alaupovitc P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation. 1990;81:470-476.
37. 37. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apoliproprotein structure and function. J Lipid Res. 1984;25:1277-1294.
38. 38. Ginsberg HN. Lipoprotein physiology and its relationship to atherogenesis. Endocrinol Metab Clin North Am. 1990;19:211-228.
39. 39. Von Eckardstein A, Huang Y, Assman G. Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol. 1994;5:404-416.
40. 40. Fielding CJ. Factors affecting the rate of catalyzed transfer of cholesteryl esters in plasma. Am Heart J 1987;113:532-537.
41. 41. Glomset JA, Janssen ET, Kennedy R, Dobbins J. Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res. 1966;7:638-648.
42. 42. Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984;25:1017-1058.
43. 43. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255-1274.
44. 44. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
45. 45. Miller NE. Association of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 1987;113:589-597.
46. 46. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochem Biophys Acta. 1981; 655:408-419.
47. 2 cholesterol subspecies and elevated postheparin hepatic lipase activity in older men with abdominal obesity and asymptomatic myocardial ischemia, Arterioscler Thromb. 1992;12:814-823.
48. 48. Wilson HM, Griffin BA, Watt C, Skinner ER. The isolation and characterization of high-density-lipoprotein subfractions containg apolipoprotein E from human plasma. Biochem J. 1992;284:477-481.
49. 49. Syvänne M, Ahola M, Lahdenperä S, Kahri J, Virtanen KS, Taskinen M-R. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res. 1995;36:573-582.
50. 50. Cheung MC, Albers JJ. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J Lipid Res. 1982;23:747-753.
51. 51. Puchois P, Kandoussi A, Fievet P, Fourrier JL, Bertrand M, Koren E, Fruchart JC. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis. 1987;68:35-40.
52. 52. Coste-Burel M, Mainard F, Chivot L, Auget JL, Madec Y. Study of lipooprotein particles LpAI and LpAI:All in patients before coronary bypass surgery. Clin Chem. 1990;36:1889-1891.
53. 53. Genest JJ Jr, Bard JM, Fruchart J-C, Ordovas JM, Wilson PFW, Schaefer EJ. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis. 1991;90:149-157.
54. 54. Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, Douste-Blazy P, Luc G, Richard JL, Ducimetiere RP, Fruchart JC, Cambien F. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: the ECTIM Study. Arterioscler Thromb. 1992;12:701-707.
55. 55. O'Brien T, Nguyen TT, Hallaway BJ, Hodge D, Bailey K, Holmes D, Kottke BA. The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler Thromb Vasc Biol. 1995; 15:228-231.
56. 56. Syvänne M, Kahri J, Virtanen KS, Taskinen M-R. HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. Circulation. 1995;92:364-370.
57. 57. Schaefer EJ, Levy RI, Anderson DW, Danner RN, Brewer HB Jr, Blackwelder WC. Plasma triglycerides in regulation of HDL-cholesterol levels. Lancet. 1978;2:391-393.
58. 58. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PWF. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res. 1994;35:871-882.
59. 59. Taskinen M-R, Kuusi T. Enzymes involved in triglyceride hydrolysis. Baillieres Clin Endocrinol Metab. 1987;1:639-666.
60. 60. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
61. 61. Tall AR. Metabolic and genetic control of HDL cholesterol levels. J Intern Med. 1992;231:661-668.
62. 2 in man. Atherosclerosis. 1980;36:589-593.
63. 3 by hepatic lipase. J Clin Invest. 1984;74:2017-2023.
64. 64. Todd PA, Ward A. Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia. Drugs. 1988;36:314-339.
65. 65. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med. 1987;83(Suppl 5B):9-20.
66. 66. Kesäniemi YA, Grundy SM. Influence of gemfibrozil and clofibrate on metabolism of cholestrol and plasma triglycerides in man. JAMA. 1984;251:2241-2246.
67. 67. Nikkilä EA, Ylikahri R, Huttunen JK. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. Proc R Soc Med. 1976;69(Suppl 2):58-63.
68. 68. Rubins HB, Robins SJ. Effect of reduction of plasma triglycerides with gemfibrozil on high-density-lipoprotein-cholesterol concentrations. J Intern Med. 1992;231: 421-426.
69. 69. Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest. 1985;75:1702-1712.
70. 70. Sorisky A, Ooi TC, Simo IE, Meuffels M, Hindmarsh JT, Nari R. Change in composition of high density lipoprotein during gemfibrozil therapy. Atherosclerosis. 1987;67:181-187.
71. 71. Mänttäri M, Koskinen P, Manninen V, Huttunen JK, Frick MH, Nikkilä EA. Effect of gemfibrozil on the concentration and composition of serum lipoproteins: a controlled study with special reference to initial triglyceride levels. Atherosclerosis. 1990;81:11-17.
72. 72. De Feyter PJ, Serruys PW7 Davies MJ, Richardson P, Lubsen J, Oliver MF. Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis: value, limitations, and implications for clinical trials. Circulation. 1991;84:412-423.
73. 73. Waters D, Craven TE, Lespérance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87:1067-1075.
74. 74. Reiber JHC, den Boer A, Serruys PW. Quality control in performing quantitative coronary arteriography. Am J Cardiac Imaging. 1989;3:172-179.
75. 75. Reiber JHC, Serruys PW,, Kooijman CJ, Wijns W, Slager CJ Gerbrands JJ, Schuurbiers JCH, den Boer A, Hugenholtz PG. Assessment of short-, medium-, and long-term variations in artierial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation. 1985;71:280-288.
76. 76. Gotto AM Jr, Breen WJ, Corder CN, Dunn JK, Goldberg A, Knopp RH, Schrott H, Sprecher D, for the Lopid SR Work Group I. Once-daily, extended-release gemfibrozil in patients with dyslipidemia. Am J Cardiol. 1993;71:1057-1063.
77. 77. Syvänne M, Nieminen MS, Frick MH. Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery: a validation study. Int J Vascular Imaging. 1994; 10:243-252.
78. 78. Frick MH, Valle M, Harjola P-T. Progression of coronary artery disease in randomized medical and surgical patients over a 5-year angiographic follow-up. Am J Cardiol. 1983;52:681-685.
79. 79. Reiber JHC, van der Zwet PMJ, von Land CD, Koning G, van Meurs B, Buis B, van Voorthuisen AE. Quantitative coronary arteriography: equipment and technical requirements. In: Reiber JHC, Serruys PW, eds. Advances in Quantitative Coronary Arteriography. Dordrecht: Kluwer Academic Publishers; 1993;75-111.
80. 80. Gibson CM, Sandor T, Stone PH, Pasternak RC, Rosner B, Sacks FM. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. Am J Cardiol. 1992;69:1286-1290.
81. 81. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
82. 82. DeLong DM, DeLong ER, Wood PD, Lippel K, Rifkind BM. A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol: the Lipid Research Clinics Prevalence Study. JAMA. 1986;256:2372-2377.
83. 83. Kashyap ML, Hynd BA, Robinson K. A rapid and simple method for measurement of total protein in the very low density lipoproteins by the Lowry assay. J Lipid Res. 1980;21:491-495.
84. 84. Parra HJ, Mezdour H, Ghalim N, Bard JM, Fruchart J-C. Differential electroimmunoassay of human Lp A-I lipoprotein particles on ready-to-use plates. Clin Chem. 1990-36:1431-1435.
85. 85. Kahri J, Vuorinen-Markkola H, Tilly-Kiesi M, Lahdenperä S, Taskinen M-R. Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin-dependent diabetes mellitus: relation to lipolytic enzymes and to the cholesteryl ester transfer protein activity. Atherosclerosis. 1993;102:79-89.
86. 86. Verdery RB, Benham DF, Baldwin HL, Goldberg AP, Nichols AV. Measurement of normative HDL subfraction cholestrol levels by Gaussian summation analysis of gradient gels. J Lipid Res. 1989;30:1085-1095.
87. 87. Nichols AV, Krauss RM, Musliner TA. Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol. 1986;128:417-431.
88. 88. Lahdenperä S, Puolakka J, Pyörälä T, Luotola H, Taskinen M-R. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles: comparison of transdermal and oral replacement regimens. Atherosclerosis., in press.
89. 89. Huttunen JK, Ehnholm C, Kinnunen PKJ, Nikkilä EA. An immunochemical method for the selective measurement of two triglyceride lipases in human posterparin plasma. Clin Chim Acta. 1975;63:335-347.
90. 90. Groener JEM, Pelton RW, Kostner GM. Improved estimation of choelesteryl ester transfer/exchange activity in serum or plasma. Clin Chem. 1986;32:283-286.
91. 91. Hannuksela M, Marcel YL, Kesäniemi YA, Savolainen MJ. Reduction in the concentration and activity of cholesterol ester transfer protein by alcohol. J Lipid Res. 1992;33:737-744.
92. 92. Havekes LM, de Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res. 1987;28:455-463.
93. 93. Jauhianen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, Huttunen JK. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59-67.
94. 94. Diabetes mellitus: report of a WHO Study Group. World Health Organization Technical report series 727, Geneva, 1985.
95. 95. Miller M, Seidler A, Kwiterovich PO, Pearson TA. Long-term predictors of subsequent cardiovascular events with coronary artery disease and "desirable" levels of plasma total cholesterol. Circulation. 1992;86:1165-1170.
96. 96. Grundy SM, Goodman DS, Rifkind BM, Cleeman JI. The place of HDL in cholesterol management: a persepective from the National Cholesterol Education Program. Arch Intern Med. 1989;149:505-510.
97. 97. Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
98. 98. Frick MH, Manninen V, Huttunen JK, Heinonen OP, Tenkanen L, Mänttäri M. HDL-cholesterol as a risk factor in coronary heart disease: an update of the Helsinki Heart Study. Drugs. 1990;40(Suppl 1):7-12.
99. 99. Rosenson RS. Low levels of high-density lipoprotein cholesterol (hypoalphalipoproteinemia): an approach to management. Arch Intern Med. 1993;153:1528-1538.
100. 100. Henry PD. Calcium channel blockers and progression of coronary artery disease. Circulation. 1990;82:2251-2253.
101. 101. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15(Suppl 5):S65-S72.
102. 102. Campeau L, Enjalbert M, Lespérance J, Bourassa MG, Kwiterovich P Jr, Wacholder S, Sniderman A. The relation of risk factor to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med. 1984;311:1329-1332.
103. 103. Van Brussel BL, Plokker HWT, Ernst SMPG, Ernst NM, Knaepen PJJ, Koomen Em Tijssen JGP, Vermeulen FEE, Voors AA. Venous coronary artery bypass surgery: a 15-year follow-up study. Circulation. 1993;88[part 2]:87-92.
104. 104. Kroncke GM, Kosolcharoen P, Clayman JA, Peduzzi PN, Detre K, Takaro T. Five-year changes in coronary arteries of medical and surgical patients of the Veterans Administration Randomized Study of Bypass Surgery. Circulation. 1988;78(Suppl I): I-144-150.
105. 105. Arnett EN, Isner JM, Redwood DR, Kent KM, Baker WP, Ackerstein H, Roberts WC. Coronary artery narrowing in coronary heart disease: comparison of cineangiographic and necropsy findings. Ann Intern Med. 1979;91:350-356.
106. 106. St. Goar FG, Pinto FJ, Alderman EL, Fitzgerald PJ, Stinson EB, Billingham ME, Popp RL. Detection of coronary atherosclerosis in young adult hearts using intravascular ultrasound. Circulation. 1992;86:756-763.
107. 107. Leung W-H, Alderman EL, Lee TC, Stadius ML. Quantitative arteriography of apparently normal coronary segments with nearby or distant disease suggests presence of occult, nonvisualized atherosclerosis. J Am Coll Cardiol. 1995;25:311-317.
108. 108. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine: results of hte International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet. 1990;335:1109-1113.
109. 109. Waters D, Lespérance J, Francetich M, Causey D, Théroux P, Chiang Y-K, Hudon G, Lemarbre L, Reitman M, Joyal M, Gosselin G, Dryda I, Macer J, Havel RJ. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 1990;82:1940-1953.
110. 2. Clin Chem. 1983;29:2026-2030.
111. 111. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-853.
112. 112. Miller M, Bachorik PS, McCrindle BW, Kwiterovich PO Jr. Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized double-bind, placebo-controlled, crossover study. Am J Med. 1993;94:7-12.
113. 113. Bredie SJH, de Bruin TWA, Demacker PNM, Kastelein JJP, Stalenhoef AFH. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol. 1995;75:348-353.
114. 114. Rubins HB, Robins SJ, Iwane MK, Boden WE, Elam MB, Fye CL, Gordon DJ, Schaefer EJ, Schectman G, Wittes JT. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol. 1993;71:45-52.
115. 115. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Weisbort J, Mandelzweig L, Abinader E, Aharon L, Braun S, David D, Flich M, Friedman Y, Kristal N, Leil N, Markeiwicz W, Marmor A, Palant A, Pelled B, Rabinowitz B, Reisin L, Roguin N, Rosenfield T, Schlesinger Z, Sclarozsky S, Sherf L, Tzivoni D, Zahavi I, Zion M, Brunner D for the Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 1993;71:909-915.
116. 116. Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH, and the CLAS investigators and staff. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Controlled Clin Trials. 1987;8:354-387.
117. 117. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH, for the Harvard Atherosclerosis Reversibility Project (HARP) Group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet. 1994;344:1182-1186.
118. 118. Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternack RC, for the HARP Research Group. Controlled trial of fish oil for regression of human coronary atherosclerosis. J Am Coll Cardiol. 1995;25:1492-1498.